Safety and tolerability of sorafenib for treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC): Detailed analyses from the phase III DECISION trial.
暂无分享，去创建一个
M. Fassnacht | M. Schlumberger | C. Nutting | Y. Ando | Y. Shong | M. Brose | F. Worden | S. Sherman | Yuankai Shi | Y. Hasegawa | J. Smit | L. Fugazzola | F. Bonichon | M. Gao | C. Kappeler | I. Molnár | D. Park | T. Hadjieva | J. Chung